US5889136A
(en)
|
1995-06-09 |
1999-03-30 |
The Regents Of The University Of Colorado |
Orthoester protecting groups in RNA synthesis
|
EP1430128B1
(en)
*
|
2001-09-28 |
2018-04-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Micro-rna molecules
|
EP2530157B1
(en)
*
|
2003-07-31 |
2016-09-28 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of miRNAs
|
US20050261217A1
(en)
|
2004-05-18 |
2005-11-24 |
Isis Pharmaceuticals Inc. |
Modulation of pumilio 1 expression
|
US7592441B2
(en)
|
2004-10-04 |
2009-09-22 |
Rosetta Genomics Ltd |
Liver cancer-related nucleic acids
|
US7825229B2
(en)
|
2005-03-25 |
2010-11-02 |
Rosetta Genomics Ltd. |
Lung cancer-related nucleic acids
|
US7642348B2
(en)
|
2004-10-04 |
2010-01-05 |
Rosetta Genomics Ltd |
Prostate cancer-related nucleic acids
|
US20070259349A1
(en)
|
2006-05-04 |
2007-11-08 |
Itzhak Bentwich |
Bladder cancer-related nucleic acids
|
PL2302055T3
(pl)
|
2004-11-12 |
2015-02-27 |
Asuragen Inc |
Sposoby i kompozycje z wykorzystaniem miRNA oraz cząsteczek inhibitorowych miRNA
|
AU2006242154B2
(en)
|
2005-05-02 |
2011-11-03 |
Cold Spring Harbor Laboratory |
Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
|
EP1904110A4
(en)
|
2005-06-03 |
2009-02-11 |
Southern Adelaide Health Servi |
TARGETING CELLS HAVING A MODIFIED EXPRESSION MICROARN
|
US20090209621A1
(en)
|
2005-06-03 |
2009-08-20 |
The Johns Hopkins University |
Compositions and methods for decreasing microrna expression for the treatment of neoplasia
|
ES2545383T3
(es)
|
2005-08-01 |
2015-09-10 |
The Ohio State University Research Foundation |
Métodos y composiciones basados en microARN para el diagnóstico, pronóstico y tratamiento de cáncer de mama
|
JP2009507918A
(ja)
|
2005-09-12 |
2009-02-26 |
ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション |
Bcl2関連癌の診断及び療法のための組成物及び方法
|
US7943318B2
(en)
|
2006-01-05 |
2011-05-17 |
The Ohio State University Research Foundation |
Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
|
JP5490413B2
(ja)
|
2006-01-05 |
2014-05-14 |
ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション |
膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロrna発現異常
|
CA2633754C
(en)
|
2006-01-05 |
2013-06-18 |
The Ohio State University Research Foundation |
Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
|
EP2522747A1
(en)
|
2006-03-02 |
2012-11-14 |
The Ohio State University |
MicroRNA expression profile associated with pancreatic cancer
|
US7985584B2
(en)
|
2006-03-20 |
2011-07-26 |
The Ohio State University Research Foundation |
MicroRNA fingerprints during human megakaryocytopoiesis
|
EA201100813A1
(ru)
|
2006-04-03 |
2012-06-29 |
Сантарис Фарма А/С |
Фармацевтическая композиция
|
WO2007112753A2
(en)
|
2006-04-03 |
2007-10-11 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
US20080076674A1
(en)
|
2006-07-06 |
2008-03-27 |
Thomas Litman |
Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
|
EP2455494B1
(en)
|
2006-07-13 |
2013-12-18 |
The Ohio State University Research Foundation |
Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
|
WO2008014008A2
(en)
|
2006-07-28 |
2008-01-31 |
The Johns Hopkins University |
Compositions and methods for modulating angiogenesis
|
EP2094848A2
(en)
|
2006-09-19 |
2009-09-02 |
Asuragen, INC. |
Mir-143 regulated genes and pathways as targets for therapeutic intervention
|
EP2076599A2
(en)
|
2006-09-19 |
2009-07-08 |
Asuragen, Inc. |
Mir-200 regulated genes and pathways as targets for therapeutic intervention
|
US8188255B2
(en)
|
2006-10-20 |
2012-05-29 |
Exiqon A/S |
Human microRNAs associated with cancer
|
EP2090665A2
(en)
|
2006-10-20 |
2009-08-19 |
Exiqon A/S |
Novel human microRNAs associated with cancer
|
US20090137504A1
(en)
|
2006-12-21 |
2009-05-28 |
Soren Morgenthaler Echwald |
Microrna target site blocking oligos and uses thereof
|
EP3536788A1
(en)
|
2006-12-21 |
2019-09-11 |
QIAGEN GmbH |
Microrna target site blocking oligos and uses thereof
|
WO2008092099A2
(en)
|
2007-01-26 |
2008-07-31 |
Rosetta Genomics, Ltd. |
Compositions and methods for treating hematopoietic malignancies
|
US20100310583A1
(en)
|
2007-01-31 |
2010-12-09 |
Immune Disease Institute |
Let-7 microrna and mimetics thereof as therapeutics for cancer
|
US9006206B2
(en)
|
2007-02-27 |
2015-04-14 |
Rosetta Genomics Ltd. |
Composition and methods for modulating cell proliferation and cell death
|
US8399248B2
(en)
|
2007-05-03 |
2013-03-19 |
Merck Sharp & Dohme Corp. |
Methods of using MIR34 as a biomarker for TP53 functional status
|
KR20100049079A
(ko)
*
|
2007-07-18 |
2010-05-11 |
더 리젠트스 오브 더 유니버시티 오브 콜로라도 |
인간의 정상 심장과 기능부진 심장에서 마이크로 rna의 차등 발현
|
US20100249213A1
(en)
|
2007-09-06 |
2010-09-30 |
The Ohio State University Research Foundation |
MicroRNA Signatures in Human Ovarian Cancer
|
CN101842484B
(zh)
|
2007-09-14 |
2015-07-29 |
俄亥俄州立大学研究基金会 |
人外周血微泡中的mirna表达和其用途
|
US8361714B2
(en)
*
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
US20090136957A1
(en)
|
2007-09-15 |
2009-05-28 |
Irena Ivanovska |
Methods and compositions for regulating cell cycle progression via the miR-106B family
|
CN101861401B
(zh)
|
2007-10-11 |
2014-03-12 |
俄亥俄州立大学研究基金会 |
用于诊断和治疗食管腺癌的方法和组合物
|
CA2704043C
(en)
|
2007-10-29 |
2018-09-18 |
Rosetta Genomics Ltd. |
Targeting micrornas for the treatment of liver cancer
|
US20110009469A1
(en)
|
2007-12-05 |
2011-01-13 |
The Johns Hopkins University |
Compositions and methods of treating neoplasia
|
EP2260109A4
(en)
|
2008-02-28 |
2011-06-08 |
Univ Ohio State Res Found |
METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR DIAGNOSING, PROGNOSING AND TREATING PROSTATE-RELATED DISORDERS
|
EP2271370A4
(en)
|
2008-03-24 |
2011-11-02 |
Univ New York |
COMPOSITIONS AND METHODS OF DIAGNOSIS AND TREATMENT OF MELANOMA
|
WO2009154835A2
(en)
|
2008-03-26 |
2009-12-23 |
Asuragen, Inc. |
Compositions and methods related to mir-16 and therapy of prostate cancer
|
US20100113284A1
(en)
|
2008-04-04 |
2010-05-06 |
Alexander Aristarkhov |
Small interfering rna (sirna) target site blocking oligos and uses thereof
|
WO2009126726A1
(en)
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
US20110166200A1
(en)
|
2008-04-24 |
2011-07-07 |
Zhan Zhang |
Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
|
EP2296669B1
(en)
|
2008-05-30 |
2012-03-21 |
Yale University |
Targeted oligonucleotide compositions for modifying gene expression
|
EP2294218A2
(en)
|
2008-06-02 |
2011-03-16 |
New York University |
Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
|
US8927207B2
(en)
*
|
2008-06-05 |
2015-01-06 |
Research Foundation Of State University Of New York |
miRNAs as therapeutic targets in cancer
|
WO2009153774A2
(en)
|
2008-06-17 |
2009-12-23 |
Rosetta Genomics Ltd. |
Compositions and methods for prognosis of ovarian cancer
|
WO2010005850A1
(en)
|
2008-07-08 |
2010-01-14 |
The J. David Gladstone Institutes |
Methods and compositions for modulating angiogenesis
|
EP2310021A4
(en)
|
2008-07-10 |
2012-06-27 |
Merck Sharp & Dohme |
METHODS OF USING COMPOSITIONS COMPRISING MIR-192 AND / OR MIR-215 FOR THE TREATMENT OF CANCER
|
WO2010023658A2
(en)
|
2008-08-28 |
2010-03-04 |
Rosetta Genomics Ltd. |
Compositions and methods for the treatment of glioblastoma
|
CN102239260B
(zh)
|
2008-10-03 |
2017-04-12 |
库尔纳公司 |
通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
|
WO2010065630A2
(en)
|
2008-12-03 |
2010-06-10 |
The Johns Hopkins University |
Compositions and methods for treating hepatic neoplasia
|
CN108042560A
(zh)
|
2008-12-04 |
2018-05-18 |
库尔纳公司 |
通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病
|
WO2010065787A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
MX2011005912A
(es)
|
2008-12-04 |
2011-06-17 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
|
CN102292456A
(zh)
|
2008-12-05 |
2011-12-21 |
俄亥俄州立大学研究基金会 |
用于诊断和治疗卵巢癌的基于microRNA 的方法和组合物
|
US20100311815A1
(en)
|
2009-02-23 |
2010-12-09 |
The Regents Of The University Of Michigan |
Mir-101 cancer markers
|
WO2010099342A2
(en)
*
|
2009-02-25 |
2010-09-02 |
Cepheid |
Methods of detecting lung cancer
|
JP6250263B2
(ja)
|
2009-03-04 |
2017-12-20 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるsirt1関連疾患の治療
|
US8735568B2
(en)
|
2009-03-09 |
2014-05-27 |
The J. David Gladstone Institutes |
Methods of modulating smooth muscle cell proliferation and differentiation
|
WO2010108192A1
(en)
|
2009-03-20 |
2010-09-23 |
The Research Foundation Of State University Of New York |
Mirnas as therapeutic targets in cancer
|
US8852940B2
(en)
*
|
2009-04-01 |
2014-10-07 |
The Regents Of The University Of California |
Embryonic stem cell specific microRNAs promote induced pluripotency
|
SG175821A1
(en)
*
|
2009-04-29 |
2011-12-29 |
Academisch Medisch Ct Bij De Univeriteit Van Amsterdam |
Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
|
WO2010127195A2
(en)
|
2009-05-01 |
2010-11-04 |
Curna, Inc. |
Antisense oligonucleotides of hemoglobins
|
WO2010129746A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
KR100998365B1
(ko)
*
|
2009-06-29 |
2010-12-06 |
압타바이오 주식회사 |
치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
|
WO2011014980A1
(en)
|
2009-08-07 |
2011-02-10 |
Capitalbio Corporation |
Methods and compositions diagnosing cervical cancer and cervical dysplasia, guidding subsequent treatment, determining prognosis, and improving patient survival
|
US8822144B2
(en)
|
2009-08-19 |
2014-09-02 |
Rosetta Genomics Ltd. |
Compositions and methods for prognosis and treatment of prostate cancer
|
WO2011024157A1
(en)
|
2009-08-23 |
2011-03-03 |
Rosetta Genomics Ltd. |
Nucleic acid sequences related to cancer
|
US9157080B2
(en)
|
2009-09-09 |
2015-10-13 |
New York University |
Compositions and methods for treatment, diagnosis and prognosis of mesothelioma
|
ES2597554T3
(es)
*
|
2009-11-04 |
2017-01-19 |
Diamir, Llc |
Métodos de utilización de micro-ARN de fluidos corporales para el diagnóstico y control del deterioro cognitivo leve
|
US9173895B2
(en)
|
2009-12-16 |
2015-11-03 |
Curna, Inc. |
Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
ES2664605T3
(es)
|
2010-01-04 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor 8 regulador del interferón (irf8) mediante inhibición del transcrito antisentido natural al gen irf8
|
US8846631B2
(en)
|
2010-01-14 |
2014-09-30 |
Regulus Therapeutics Inc. |
MicroRNA compositions and methods
|
JP5981850B2
(ja)
|
2010-01-25 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療
|
CN102844435B
(zh)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
|
EP3214174B1
(en)
*
|
2010-03-04 |
2019-10-16 |
InteRNA Technologies B.V. |
A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
|
US20130059015A1
(en)
|
2010-03-11 |
2013-03-07 |
H. Lee Moffitt Cancer Center & Research Institute |
Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
|
US9526693B2
(en)
|
2010-03-16 |
2016-12-27 |
Sanford-Burnham Medical Research Inslilute |
Delivery of agents using interfering nanoparticles
|
CN102858979B
(zh)
|
2010-04-09 |
2018-01-26 |
库尔纳公司 |
通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
|
WO2011128886A1
(en)
|
2010-04-12 |
2011-10-20 |
Ramot At Tel Aviv University Ltd. |
A micro-rna for cancer diagnosis, prognosis and therapy
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
TW201201819A
(en)
|
2010-05-19 |
2012-01-16 |
Opko Curna Llc |
Treatment of BCL2-like 11 (BCL2L11) related diseases by inhibition of natural antisense transcript to BCL2L11
|
CN107412251A
(zh)
|
2010-05-26 |
2017-12-01 |
库尔纳公司 |
通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病
|
WO2011157294A1
(en)
|
2010-06-16 |
2011-12-22 |
Universita' Degli Studi Di Padova |
Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
|
WO2012009347A2
(en)
|
2010-07-12 |
2012-01-19 |
Opko Curna Llc |
Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
|
WO2012009508A2
(en)
|
2010-07-15 |
2012-01-19 |
Emory University |
Microrna compositions and methods related thereto
|
US20130123138A1
(en)
|
2010-07-25 |
2013-05-16 |
New York University |
Compositions and methods for prognosis of mesothelioma
|
WO2012017430A2
(en)
|
2010-08-01 |
2012-02-09 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Microrna patterns for the diagnosis, prognosis and treatment of melanoma
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
KR101343616B1
(ko)
|
2010-10-08 |
2013-12-20 |
연세대학교 산학협력단 |
췌장암 치료용 약제학적 조성물 및 췌장암 치료제 스크리닝 방법
|
EP2638163B1
(en)
|
2010-11-12 |
2017-05-17 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
JP2014502606A
(ja)
|
2010-12-15 |
2014-02-03 |
メディミューン,エルエルシー |
黒色腫の処置
|
WO2012092485A1
(en)
*
|
2010-12-31 |
2012-07-05 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory rna molecules
|
WO2012093384A1
(en)
|
2011-01-03 |
2012-07-12 |
Rosetta Genomics Ltd. |
Compositions and methods for treatment of ovarian cancer
|
EP2474617A1
(en)
*
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
MX2013008944A
(es)
*
|
2011-02-03 |
2014-01-08 |
Mirna Therapeutics Inc |
Mimeticos sinteticos de mir-124.
|
US9132152B2
(en)
|
2011-02-10 |
2015-09-15 |
The Regents Of The University Of California |
Compositions and methods for generating induced pluripotent stem cells
|
US20120264131A1
(en)
|
2011-03-18 |
2012-10-18 |
Baylor Research Institute |
CHANGES IN THE EXPRESSION OF miR-200c/141 CLUSTER OF microRNAs AS BIOMARKERS FOR EPITHELIAL-TO-MESENCHYMAL TRANSITION IN HUMAN COLORECTAL CANCER METASTASIS
|
US8987224B2
(en)
*
|
2011-08-05 |
2015-03-24 |
Baylor College Of Medicine |
MicroRNA-198 as a tumor suppressor in pancreatic cancer
|
US20150267193A1
(en)
*
|
2011-10-14 |
2015-09-24 |
Ramanuj Dasgupta |
MicroRNAs and Methods of Using Same
|
EP2785355A4
(en)
|
2011-11-30 |
2015-12-02 |
Cedars Sinai Medical Center |
TARGETING OF MICRORNAS MIR-409-5P, MIR-379 AND MIR-154 * FOR THE TREATMENT OF PROSTATE CANCER BONE MESTASTAS AND DRUG-RESISTANT LUNG CANCER
|
US9745578B2
(en)
|
2011-11-30 |
2017-08-29 |
Cedars-Sinai Medical Center |
Targeting microRNA miR-409-3P to treat prostate cancer
|
WO2013109604A1
(en)
*
|
2012-01-19 |
2013-07-25 |
Alnylam Pharmaceuticals, Inc. |
Viral attenuation and vaccine production
|
EP2825648B1
(en)
|
2012-03-15 |
2018-09-05 |
CuRNA, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
SG11201406787TA
(en)
*
|
2012-04-20 |
2014-12-30 |
Agency Science Tech & Res |
Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
|
CA2873797A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating utrn expression
|
BR112014028647A2
(pt)
|
2012-05-16 |
2017-07-25 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão de bdnf
|
AU2013262649A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
BR112014028645A2
(pt)
|
2012-05-16 |
2017-06-27 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão de apoa1 e abca1.
|
EP2850187A4
(en)
|
2012-05-16 |
2016-01-20 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHODS FOR PTEN EXPRESSION MODULATION
|
US10174315B2
(en)
|
2012-05-16 |
2019-01-08 |
The General Hospital Corporation |
Compositions and methods for modulating hemoglobin gene family expression
|
WO2013173608A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating mecp2 expression
|
CN104583398A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节基因表达的组合物和方法
|
US10174323B2
(en)
|
2012-05-16 |
2019-01-08 |
The General Hospital Corporation |
Compositions and methods for modulating ATP2A2 expression
|
CA2882428A1
(en)
|
2012-07-12 |
2014-01-16 |
Baylor College Of Medicine |
Micrornas sensitize cancers to therapy
|
US9096853B2
(en)
*
|
2012-09-24 |
2015-08-04 |
U.S. Department Of Veterans Affairs |
Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity
|
WO2014071067A2
(en)
|
2012-10-31 |
2014-05-08 |
The Rockefeller University |
Treatment and diagnosis of colon cancer
|
EP2917348A1
(en)
|
2012-11-06 |
2015-09-16 |
InteRNA Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
WO2014100252A1
(en)
*
|
2012-12-18 |
2014-06-26 |
University Of Washington Through Its Center For Commercialization |
Methods and compositions to modulate rna processing
|
US10697020B2
(en)
*
|
2013-05-15 |
2020-06-30 |
The Research Foundation For The State University Of New York |
MicroRNA-129 as a biomarker for colorectal cancer
|
AU2014274730A1
(en)
|
2013-06-07 |
2016-01-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating FOXP3 expression
|
WO2014201417A1
(en)
*
|
2013-06-14 |
2014-12-18 |
The University Of Kansas |
Methods and compositions of modulating tumor initiating cells and the use thereof
|
PL3074050T3
(pl)
*
|
2013-10-28 |
2021-04-06 |
Icahn School Of Medicine At Mount Sinai |
Kompozycje i sposoby modulowania pobudliwości neuronalnej i zachowania motorycznego
|
WO2015095862A2
(en)
|
2013-12-20 |
2015-06-25 |
The Feinstein Institute For Medical Research |
Microrna biomarkers for ovarian cancer
|
JP2017511694A
(ja)
|
2014-02-12 |
2017-04-27 |
トーマス・ジェファーソン・ユニバーシティ |
マイクロrna阻害剤を使用するための組成物および方法
|
KR101596166B1
(ko)
|
2014-10-07 |
2016-02-19 |
가톨릭대학교 산학협력단 |
유방암 진단 및 치료를 위한 마이크로 rna의 용도
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
EP3331546B1
(en)
|
2015-08-03 |
2023-10-04 |
Biokine Therapeutics Ltd. |
Cxcr4 inhibitor for the treatment of cancer
|
US10053696B2
(en)
|
2016-01-21 |
2018-08-21 |
University Of South Carolina |
MiRNA-489 in treatment of breast cancer
|
MX2019005101A
(es)
|
2016-11-01 |
2019-08-22 |
Univ New York State Res Found |
Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
|
US11236337B2
(en)
|
2016-11-01 |
2022-02-01 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
US10443055B2
(en)
|
2016-12-22 |
2019-10-15 |
Beth Israel Deaconess Medical Center |
Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
|
US10988766B2
(en)
|
2017-01-06 |
2021-04-27 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
WO2018136919A2
(en)
|
2017-01-23 |
2018-07-26 |
Trustees Of Boston University |
Methods relating to lung cancer
|
KR101953300B1
(ko)
|
2018-06-22 |
2019-02-28 |
의료법인 성광의료재단 |
탁산계 항암제 내성 암의 진단 및 치료를 위한 조성물, 키트 및 방법
|
MA53669A
(fr)
|
2018-09-20 |
2021-07-28 |
Modernatx Inc |
Compositions et procédés d'administration d'acides nucléiques
|
MA54226A
(fr)
|
2018-11-13 |
2021-09-22 |
Regulus Therapeutics Inc |
Composés de microarn et méthodes de modulation de l'activité du mir-10b
|
WO2020154207A1
(en)
|
2019-01-22 |
2020-07-30 |
Research Institute At Nationwide Children's Hospital |
A novel method for monitoring and treating oral cancer
|
JP2022525156A
(ja)
|
2019-03-14 |
2022-05-11 |
ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク |
修飾されたマイクロrna及びがんの処置におけるその使用
|
US20220275374A1
(en)
|
2019-11-14 |
2022-09-01 |
The Board Of Regents Of The University Of Oklahoma |
Oligonucleotide interference treatments of prostate cancer
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
WO2021262919A2
(en)
|
2020-06-26 |
2021-12-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified micrornas and their use in the treatment of cancer
|